G

Guobang Pharma Ltd
SSE:605507

Watchlist Manager
Guobang Pharma Ltd
SSE:605507
Watchlist
Price: 21.27 CNY -3.23% Market Closed
Market Cap: 11.8B CNY
Have any thoughts about
Guobang Pharma Ltd?
Write Note

Guobang Pharma Ltd
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Guobang Pharma Ltd
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
G
Guobang Pharma Ltd
SSE:605507
Total Other Income
ÂĄ468k
CAGR 3-Years
-67%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Other Income
-ÂĄ25m
CAGR 3-Years
-77%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Other Income
-ÂĄ372.4m
CAGR 3-Years
-53%
CAGR 5-Years
-28%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Other Income
-ÂĄ2.8m
CAGR 3-Years
19%
CAGR 5-Years
36%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Other Income
ÂĄ649.7k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Guobang Pharma Ltd
Glance View

Market Cap
11.8B CNY
Industry
Pharmaceuticals

Guobang Pharma Ltd. engages in the research, development, manufacturing and sale of pharmaceutical products. The company is headquartered in Shaoxing, Zhejiang and currently employs 3,326 full-time employees. The company went IPO on 2021-08-02. The firm's pharmaceutical business includes raw materials, key pharmaceutical intermediates and preparations, and its main products include azithromycin, clarithromycin, and roxithromycin cephalosporin series products. The animal health products business includes animal protection raw materials, animal protection additives and preparations. The main products of veterinary antibiotics include florfenicol, enrofloxacin series, etc., and insecticides include diclazuril and cypronamine, and reparation products include premixes, powders, granules, etc.

Intrinsic Value
34.07 CNY
Undervaluation 38%
Intrinsic Value
Price
G

See Also

What is Guobang Pharma Ltd's Total Other Income?
Total Other Income
468k CNY

Based on the financial report for Dec 31, 2023, Guobang Pharma Ltd's Total Other Income amounts to 468k CNY.

What is Guobang Pharma Ltd's Total Other Income growth rate?
Total Other Income CAGR 3Y
-67%

The average annual Total Other Income growth rates for Guobang Pharma Ltd have been -67% over the past three years .

Back to Top